Ammonia gas sensors based on undoped and Ca-doped ZnO nanoparticles.

Due to its large use in different industrial sectors, high toxicity, and corrosion, the demand for sensing techniques towards ammonia gas has become urgent. In this study we report on the sensing performances of a conductometric sensor for NH3 gas based on Ca-doped ZnO nanoparticles with different calcium concentrations (0, 1, and 3 at%) synthesized using the sol-gel process under supercritical dry conditions of ethanol. All samples were characterized using X-ray diffraction (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM), and Fourier-transform infrared (FTIR) spectroscopy. Pure and Ca-doped ZnO are polycrystalline and well crystallized in the hexagonal wurtzite structure. TEM images revealed that pure ZnO is composed of spherical particles with dimensions in the nanometer range. Larger particles were observed after the incorporation of Ca ions. The average crystallite size, estimated by the Williamson-Hall method, was 43, 80, and 96 nm for pure, Ca-1 at% and Ca-3 at%, respectively. Furthermore, FTIR spectroscopy was used to prove the formation of ZnO and the incorporation of calcium ions in the Ca-doped ZnO samples. The gas sensing performances towards ammonia gas clearly ameliorated after the addition of Ca ions in the ZnO structure. The gas response to NH3, R0/Rg, of the 1% Ca-doped ZnO sensor reached a value of 33 for 4000 ppm of ammonia at T = 300 °C with good selectivity compared to other gases such as CO, CO2, and NO2. The response and recovery times were 5 s and 221 s, respectively. The reported good sensing performances indicate the potential application of Ca-doped ZnO as a sensor material for ammonia detection.

Superior removal of dyes by mesoporous MgO/g-C3N4 fabricated through ultrasound method: Adsorption mechanism and process modeling.

The present research concerns the synthesis of a mesoporous composite characterized with high surface area and superior adsorption capacity in order to investigate its efficacity in removing hazardous and harmful dyes molecules from water. The synthesized mesoporous composite, MgO/g-C3N4 (MGCN), was successfully prepared through the sonication method in a methanolic solution followed by an evaporation and a calcination process. The configuration, crystalline phase, surface properties, chemical bonding, and morphological study of the fabricated nanomaterials were investigated via XRD, BET, FESEM, HRTEM, XPS, and FTIR instrumentation. The obtained nanomaterials were used as sorbents of Congo Red (CR) and Basic Fuchsin (BF) dyes from aqueous solutions. Batch elimination experimental studies reveal that the elimination of CR and BF dyes from an aqueous solution onto the MGCN surface was pH-dependent. The highest removal of CR and BF pollutants occurs, respectively, at pH 5 and 7. The absorptive elimination of CR and BF dyes into the MGCN surface was well-fitted with a pseudo-second-order kinetics and Langmuir model. In this concern, the maximum nanocomposite elimination capacity for CR and BF was observed to be 1250 and 1791 mg g-1, respectively. This investigation confirms that MGCN composite is an obvious and efficient adsorbent of CR, BF, and other organic dyes from wastewater.

Bacterial adhesion and inactivation on Ag decorated TiO2-nanotubes under visible light: Effect of the nanotubes geometry on the photocatalytic activity.

This study investigates the effect of the diameter of TiO2 nanotubes and silver decorated nanotubes on optical properties and photocatalytic inactivation of Escherichia coli under visible light. The TiO2 nanotubes (TiO2-NTs) were prepared using the electrochemical method varying the anodization potential starting from 20 V until 70 V. The Ag nanoparticles were carried out using the photoreduction process under the same experimental conditions. The diameter size was determined using the scanning electronic microscopy (SEM). TiO2-NTs diameter reached ∼100 nm at 70 V. Transmission electronic microscopy (TEM) imaging confirmed the TiO2-NTs surface decoration by silver nanoparticles. The Ag-NPs average size was found to be equal to 8 nm. The X-Ray diffraction (XRD) analysis confirm that all TiO2-NTs crystallize in the anatase phases regardless the used anodization potential. The decrease of the photoluminescence (PL) intensity of Ag NPs decorated TiO2-NTs indicates the decrease of the specific area when the nanotubes diameter increases. The UV-vis absorbance show that the absorption edges was bleu shifted with the increasing of nanotubes diameter, which can be explained by the increase of the crystallites average size. The bacterial adhesion and inactivation tests were carried in the dark and under light. Bacteria were seen to adhere on TiO2-NTs in the dark; however, under light the bacteria were killed before they establish a strong contact with the TiO2-NTs and Ag/TiO2-NTs surfaces. Bacterial inactivation kinetics were faster when the anodizing potential of the NTs-preparation increases. A total bacterial inactivation was obtained on ∼100 nm nanotubes diameter within 90 min. This result was attributed to the enhancement of the TNTs crystallinity leading to reduced surface defects. Redox catalysis was seen to occur under light on the TiO2-NTs and Ag/TiO2-NTs. the photo-induced antibacterial activity on the AgO/Ag2O decorated TiO2-NTs was attributed to the interfacial charge transfer mechanism (IFCT).

Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.

Cholinergic neurons degenerate in Alzheimer's disease, resulting in cognitive impairments and memory deficits, and drug development efforts have focused on selective M1 muscarinic agonists. 5-(3-Ethyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine trifluoroacetic acid (CDD-0102) stimulates M1 muscarinic receptors in rat brain [Messer, W.S., Jr., Abuh, Y.F., Liu, Y., Periyasamy, S., Ngur, D.O., Edgar, M.A., El-Assadi, A.A., Sbeih, S., Dunbar, P.G., Roknich, S., Rho, T., Fang, Z., Ojo, B., Zhang, H., Huzl, J.J., III, Nagy, P.I., 1997a. J. Med. Chem. 40, 1230-1246.] and improves memory function in rats with lesions of the basal forebrain cholinergic system. Moreover, CDD-0102 exhibits oral bioavailability, few side effects and low toxicity, and thus represents a viable candidate for clinical studies. Despite the development of functionally selective agonists such as xanomeline and CDD-0102, there is room for improvements in ligand affinity and selectivity. The high degree of amino acid homology within transmembrane domains has hindered the development of truly selective agonists. Site-directed mutagenesis, biochemical and molecular modeling studies have identified key amino acid residues such as Thr192 and Asn382 in the binding of agonist to M1 receptors [Huang, X.P., Nagy, P.I., Williams, F.E., Peseckis, S.M., Messer, W.S., Jr., 1999. Br. J. Pharmacol. 126, 735-745.]. Recent work has implicated residues at the top of transmembrane domain VI in the binding of muscarinic agonists and activation of M1 receptors [Huang, X.P., Williams, F.E., Peseckis, S.M., Messer, W.S., Jr., 1998. J. Pharmacol. Exp. Ther. 286, 1129-1139.]. Thus, residues such as Ser388 represent molecular targets for the further development of agonists with improved M1 receptor affinity, selectivity and activity.

Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.

Previous studies identified several novel tetrahydropyrimidine derivatives exhibiting muscarinic agonist activity in rat brain. Such compounds might be useful in treating cognitive and memory deficits associated with low acetylcholine levels, as found in Alzheimer's disease. To determine the molecular features of ligands important for binding and activity at muscarinic receptor subtypes, the series of tetrahydropyrimidines was extended. Several active compounds were examined further for functional selectivity through biochemical studies of muscarinic receptor activity using receptor subtypes expressed in cell lines. Several amidine derivatives displayed high efficacy at m1 receptors and lower activity at m3 receptors coupled to phosphoinositide (PI) metabolism in A9 L cells. Four ligands, including 1b, 1f, 2b, and 7b, exhibited marked functional selectivity for m1 vs m3 receptors. Compound 1f also exhibited low activity at m2 receptors coupled to the inhibition of adenylyl cyclase in A9 L cells. Molecular modeling studies also were initiated to help understand the nature of the interaction of muscarinic agonists with the m1 receptor using a nine amino model of the m1 receptor. Several important interactions were identified, including interactions between the ester moiety and Thr192. Additional interactions were found for oxadiazoles and alkynyl derivatives with Asn382, suggesting that enhanced potency and selectivity may be achieved by maximizing interactions with Asp105, Thr192, and Asn382. Taken together, the data indicate that several amidine derivatives display functional selectivity for m1 muscarinic receptors, warranting further evaluation as therapeutic agents for the treatment of Alzheimer's disease. In addition, several amino acid residues were identified as potential binding sites for m1 agonists. These data may be useful in directing efforts to develop even more selective m1 agonists.

Synthesis and biochemical activity of novel amidine derivatives as m1 muscarinic receptor agonists.

As part of a continuing effort aimed at the development of selective, efficacious, and centrally active m1 muscarinic agonists for the treatment of Alzheimer's disease, a series of amide and hydrazide amidine derivatives (2a-e and 3b-d) was synthesized and examined for muscarinic agonist activity. Preliminary biochemical studies indicated that 2b, 2d, and 3d bound to muscarinic receptors in rat brain and stimulated phosphoinositide (PI) metabolism in rat cerebral cortex. Compounds 2b and 2d were also highly efficacious at m1 muscarinic receptors expressed in cultured A9 L cells. Molecular modeling studies suggest slightly different modes of interaction with m1 receptors for the ester and amide derivatives. Also, hydrogen-bond formation with a Thr residue may be important for m1 muscarinic agonist potency. The data suggest that the amide moiety can replace the ester group found in muscarinic agonists and provide further support for the utility of amidine derivatives in the development of efficacious m1 agonists.

Anticonvulsant activity of novel derivatives of 2- and 3-piperidinecarboxylic acid in mice and rats.

The relative ability of derivatives of 2-piperidinecarboxylic acid (2-PC; pipecolic acid) and 3-piperidinecarboxylic acid (3-PC; nipecotic acid) to block maximal electroshock (MES)-induced seizures, elevate the threshold for electroshock-induced seizures and be neurotoxic in mice was investigated. Protective index (PI) values, based on the MES test and rotorod performance, ranged from 1.3 to 4.5 for 2-PC benzylamides and from < 1 to > 7.2 for 3-PC derivatives. PI values based on elevation of threshold for electroshock-induced seizures and rotorod performance ranged from > 1.6 to > 20 for both types of derivatives. Since preliminary data indicated that benzylamide derivatives of 2-PC displace [3H]1-[1-(2-thienyl)-cyclohexyl]piperidine (TCP) binding to the phencyclidine (PCP) site of the N-methyl-D-aspartate (NMDA) receptor in the micromolar range and such low affinity uncompetitive antagonists of the NMDA receptor-associated ionophore have been shown to be effective anticonvulsants with low neurological toxicity, the 2-PC derivatives were evaluated in rat brain homogenates for binding affinity to the PCP site. Although all compounds inhibited [3H]TCP binding, a clear correlation between pharmacological activity and binding affinity was not apparent. Select compounds demonstrated minimal ability to protect against pentylenetetrazol-, 4-aminopyridine- and NMDA-induced seizures in mice. Corneal and amygdala kindled rats exhibited different sensitivities to both valproic acid and the nonsubstituted 2-PC benzylamide, suggesting a difference in these two models. Enantiomers of the alpha-methyl substituted benzylamide of 2-PC showed some ability to reduce seizure severity in amygdala kindled rats.

Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.

Four regioisomers of 2-amino-(methoxycarbonyl)-3,4,5,6-tetrahydropyridine (2a-5a) were synthesized as the racemates to evaluate the utility of exocyclic amidines in the development of novel agonists for M1 muscarinic receptors. Of the four regioisomers, only racemic 2-amino-5-(methoxycarbonyl)-3,4,5,6-tetrahydropyridine (4a; CDD-0075-A) displayed high affinity (IC50 = 10 +/- 3.0 microM) and activity at muscarinic receptors coupled to PI metabolism in the rat cortex (260 +/- 4.5% stimulation above basal levels at 100 microM). A series of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines then was synthesized for further evaluation as M1 agonists. Only the propargyl derivative (4d) retained substantial agonist activity (120 +/- 14% at 100 microM) in this series. On the basis of the activity of the 5-(alkoxycarbonyl)-1,4,5,6- tetrahydropyrimidines (1a and 1d) and the 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines, the corresponding cyclic guanidine derivatives were synthesized and tested. 2-Amino-5-(methoxycarbonyl)-1,4,5,6-tetrahydropyrimidine (7a) displayed a modest affinity for muscarinic receptors in the CNS (22 +/- 5.3 microM) and an ability to stimulate PI turnover in rat cerebral cortex (81 +/- 16% at 100 microM). The propargyl derivative (7d) also had modest binding affinity (31 +/- 15 microM) and high activity (150 +/- 8.5% at 100 microM), as expected based on the activity of propargyl esters of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine. Computational chemical studies revealed five distinct minimum-energy conformations for 1a, (R)-4a, and 7a, and three for 1d, (R)-4d, and 7d, each with a unique orientation of the ester moiety. Each of the five conformations for 1a could be superimposed upon a unique conformer of (R)-4a and 7a, suggesting that the compounds interact with muscarinic receptors in a similar fashion. Taken together, the data indicate the general utility of amidine systems as suitable replacements for the ammonium group of acetylcholine in developing ligands with activity at M1 muscarinic receptors in the central nervous system. Such compounds might be useful in the treatment of patients with Alzheimer's disease.

Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.

A series of 5-(3-alkyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines+ ++ (7a-h) was synthesized for biological evaluation as selective agonists for M1 receptors coupled to phosphoinositide (PI) metabolism in the central nervous system. Each ligand bound with high affinity to muscarinic receptors from rat brain as measured by inhibition of [3H]-(R)-quinuclidinyl benzilate ([3H]-(R)-QNB) binding. 5-(3-Methyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine+ ++ trifluoroacetate (CDD-0098-J;7a) displayed high affinity (IC50 = 2.7 +/- 0.69 microM) and efficacy at muscarinic receptors coupled to PI metabolism in the rat cortex and hippocampus. Increasing the length of the alkyl substituent increased affinity for muscarinic receptors yet decreased activity in PI turnover assays. The hippocampal PI response of 7a was blocked by lower concentrations of pirenzepine (8) or by higher concentrations of either AF-DX 116 (9) or p-fluorohexahydrosiladifenidol (10), suggesting that at low concentrations 7a selectively stimulates PI turnover through M1 receptors.